Calendario›REGN›REGN15505

REGN15505

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Ensayo de REGENERON PHARMACEUTICALS, INC. en Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Clear Cell Renal Cell Carcinoma (ccRCC) (del registro, en inglés).

Fase

Fase 1/2

Estado

Reclutando pacientes

Participantes

265

previstos

Centros

6

Fin del objetivo primario

oct 2030

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jul 2026.

Qué mide

Occurrence of Dose Limiting Toxicities (DLTs) (del registro, en inglés) (hasta 5 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07594106), actualizada en sep 2026.